Burger King Colombia has partnered with Chilean plant-based company NotCo to offer flexitarians the Veggie Whopper, King Veggie, and Nuggets Veggie.
The deal helps expand the plant-based movement across Latin America.
Using the slogan “We declare ourselves Flexitarians!”, Burger King is promoting the new options as 100 percent plant-based, although it’s yet unspecified if the bread and sauces are vegan.
Meanwhile, in announcing the new veggie line from Burger King on social media, NotCo insists that “more and more people believe that removing animals from the equation is the answer for a more sustainable yet equally delicious world.”
NotCo has partnered with Burger King Chile to launch plant-based chicken sandwiches and nuggets, with BK Peru to bring its plant-based burger patties to the country, and with Starbucks Mexico in introducing its plant-based NotChicken Baguette and NotBurger Baguette.


WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions
9 Tips for Avoiding Tax Season Cyber Scams
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Australia's Inflation Eases in February but Core Pressures Persist
The Beauty Beneath the Expressway: A Journey from Self to Service
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



